BMS-265246

BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC50 values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases) . BMS-265246 can be used for ovarian cancer and COVID-19 research[1][2][3].

Product Specifications

CAS Number

[582315-72-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin-converting Enzyme (ACE) ; CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/bms-265246.html

Purity

99.59

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

CC1=CC(F)=C(C(C2=CN=C(NN=C3)C3=C2OCCCC)=O)C(F)=C1

Molecular Formula

C18H17F2N3O2

Molecular Weight

345.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Misra RN, Xiao H, Rawlins DB et al. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues. Bioorg Med Chem Lett. 2003 Jul 21;13 (14) :2405-8.|[2]Gu H, et al. Inhibition of CDK2 promotes inducible regulatory T-cell differentiation through TGFβ-Smad3 signaling pathway. Cell Immunol. 2014 Jul;290 (1) :138-44. |[3]Kamle S, et al. Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19. JCI Insight. 2021 Nov 8;6 (21) :e148749.|[4]Scott GK, et al. ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition. Oncotarget. 2016 Oct 18;8 (48) :83432-83445.